Company news
Avecho Biotechnology Limited (ASX:AVE) news
Avecho Biotechnology Limited news releases on 6ix. Latest, Apr 28, 2023: March 2023 Quarterly Activities Report & Appendix 4C
Press releases — page 2
March 2023 Quarterly Activities Report & Appendix 4C
April 27, 2023
Investor Presentation
April 3, 2023
Prospectus
April 3, 2023
Entitlement Offer to raise $11m for Phase 3 clinical trial
April 3, 2023
Clinical CBD program expands with the Lambert Initiative
February 21, 2023
December 2022 Quarterly Activities Report & Appendix 4C
January 30, 2023
Athenex submits Avechos phytonadione to FDA pre-IND
January 12, 2023
Avecho receives ethics approval for Phase III CBD trial
December 21, 2022
AVE signs development agreement with Perrigo
December 19, 2022
September 2022 Quarterly Activities Report & Appendix 4C
October 27, 2022
Increased CBD absorption in dogs vs commercial comparator
September 19, 2022
June 2022 Quarterly Activities Report & Appendix 4C
July 28, 2022
Security Class Reinstatement to Quotation- AVEO
July 14, 2022
Update on Listed Options and Federal Court Application
July 14, 2022
Suspension from Official Quotation - AVEO
June 8, 2022
March 2022 Quarterly Activities Report & Appendix 4C
April 28, 2022
Positive results from AVEs topical CBD pain study
March 28, 2022
Dosing begins in topical CBD pain study
February 28, 2022
Appendix 4E and Annual Report 31 December 2021
February 27, 2022
AVE license agreement for US recreational cannabis market
February 2, 2022
December 2021 Quarterly Activities Report & Appendix 4C
January 30, 2022
Avecho Biotechnology : Application for quotation of securities - AVE
January 9, 2022
AVE Licenses CBD Soft-Gel to Medterra Pharma for Arthritis
December 20, 2021
Positive results from Avechos Phase I trial of CBD soft-gel
December 7, 2021
September 2021 Quarterly Activities Report & Appendix 4C
October 28, 2021
Topical CBD pain study with Lambert Initiative approved
October 20, 2021
Dosing begins in Phase I PK trial testing CBD soft-gel
October 3, 2021
Phase I clinical trial testing CBD product-enrolment begins
September 14, 2021
June 2021 Quarterly Activities Report & Appendix 4C
July 26, 2021
Avecho to Present New CBD Data at GCI Virtual Summit
June 8, 2021
Chairs Address and CEO Presentation
May 31, 2021
AB Vista to explore new TPM applications for Animal Health
May 30, 2021
TGA meeting for CBD soft-gel targeting insomnia
May 25, 2021
Avecho completes pharmaceutical CBD soft-gel product
May 20, 2021
March 2021 Quarterly Activities Report & Appendix 4C
April 28, 2021
Avecho receives ethics approval for CBD human trial
April 12, 2021
AVE receives firm commitment to raise $5.06 via placement
February 9, 2021
December 2020 Quarterly Activities Report & Appendix 4C
January 29, 2021
AVE begins Human Trial on CBD product
December 22, 2020
Improved Propofol TPM Formulation Passes Toxicology Study
November 3, 2020
September 2020 Quarterly Activities Report & Appendix 4C
October 28, 2020
TPM Cannabinoid Development Program Update
October 18, 2020
Progress Update for TPM Cannabinoid Development Program
August 19, 2020
June 2020 Quarterly Activities Report & Appendix 4C
July 28, 2020
March 2020 Quarterly Activities Report & Appendix 4C
April 28, 2020
Changes to Leadership Team
April 26, 2020
Avecho signs Term Sheet for Cannabinoid Supply with Purisys
April 13, 2020
Appendix 4E and Annual Report 31 December 2019
March 1, 2020
Appendix 4C - Quarterly
January 22, 2020
Injectable Portfolio Update - Products Differentiated by TPM
December 4, 2019